The Ultomiris Drug Market is experiencing significant growth due to the increasing prevalence of rare autoimmune and hematologic disorders, rising awareness about complement-mediated diseases, and advancements in biologic therapies. Ultomiris (ravulizumab), a long-acting complement C5 inhibitor, has emerged as a breakthrough treatment for several life-threatening conditions, driving...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek